文献速递儿童血液肿瘤与免疫

儿童B-ALL伴MEF2D基因重排9例临床分析

[Clinical analysis of 9 children of B-cell acute lymphoblastic leukemia with MEF2D gene rearrangement].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2026-01-01

该病例系列研究纳入2020年5月至2025年6月郑州大学第一附属医院收治的9例伴MEF2D基因重排初诊B-ALL患儿,分析其临床特征、分子遗传学、治疗及转归。结果显示患儿多为大龄儿童,常以发热伴关节疼痛起病,均高表达CD38且不表达cIgM,CDKN2A/CDKN2B缺失发生率高;诱导治疗结束时流式MRD均阴性,但3例复发后死亡,提示该亚型复发风险高且挽救治疗疗效有限。

要点

  • MEF2D重排B-ALL多见于大龄儿童,常以发热伴关节疼痛起病。
  • 免疫表型为CD38高表达、cIgM不表达,CDKN2A/CDKN2B缺失发生率高。
  • 初始治疗反应良好但复发风险高,可探索二代测序监测MRD。

核心结论

  • 伴MEF2D基因重排的儿童B-ALL多见于大龄儿童,常以发热伴关节疼痛起病,高表达CD38且不表达cIgM,CDKN2A或CDKN2B基因缺失发生率高。
  • 尽管初始治疗反应良好,但复发风险高且挽救治疗疗效有限,采用二代测序进行微小残留病监测或许可更准确评估复发风险。

研究设计与样本

  • 病例系列研究,收集2020年5月至2025年6月郑州大学第一附属医院收治的9例伴MEF2D基因重排初诊B-ALL患儿资料。
  • 系统分析患儿临床特征、实验室检查、治疗方案及转归情况。

主要发现

  • 9例患儿男3例、女6例,诊断年龄12.0(11.0,13.8)岁,5例以发热伴关节疼痛起病。
  • 免疫分型示1例为早期前B-ALL、其余8例为普通B-ALL,9例均高表达CD38且不表达cIgM,5例骨髓涂片可见细胞空泡。
  • RNA测序检测到5种MEF2D融合伙伴:BCL9基因4例、FOXJ2基因2例、DAZAP1基因、SS18基因及ARNT基因各1例。
  • 6例检出CDKN2A或CDKN2B基因杂合缺失,8例合并基因变异。
  • 9例均按2018儿童急性淋巴细胞白血病诊疗规范给予VDLP方案诱导治疗,诱导缓解结束时流式细胞术检测MRD均阴性(<0.01%);1例维持治疗阶段失访,3例复发后死亡,随访至2025年10月10日2例无病生存、3例规律治疗中。

关键数值与推荐

  • 所有9例均按照「2018儿童急性淋巴细胞白血病诊疗规范」给予VDLP(长春新碱、柔红霉素、培门冬酶、泼尼松)方案诱导治疗。
  • 诱导缓解治疗结束时经流式细胞术检测微小残留病均阴性(<0.01%)。

临床怎么用

  • 对伴MEF2D基因重排的B-ALL患儿应认识到其大龄儿童为主、发热伴关节疼痛起病及CD38高表达、cIgM不表达的特征。
  • 尽管诱导治疗反应良好,仍需警惕高复发风险,可探索采用二代测序进行微小残留病监测以更准确评估复发风险。

局限性

  • 本研究为单中心病例系列研究,样本量仅9例。
  • 1例患儿维持治疗阶段失访,随访时间截至2025年10月10日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To summarize the clinical characteristics, molecular genetic features, diagnosis and treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL) with myocyte enhancer factor 2D (MEF2D) gene rearrangement. Methods: In this case series study, clinical data of 9 children newly diagnosed B-ALL with MEF2D gene rearranged, admitted to the First Affiliated Hospital of Zhengzhou University from May 2020 to June 2025 were collected. The clinical characteristics, laboratory findings, treatment regimens, and outcomes of these patients were systematically analyzed. Results: A total of 9 chlidren were enrolled (3 boys and 6 girls), with the diagnostic age of 12.0 (11.0, 13.8) years. Five children initially presented with fever accompanied by arthralgia. Immunophenotyping revealed that 1 child was early precursor B-ALL and the remaining 8 children were common B-ALL. Uniformly high expression of CD38 and absence of cytoplasmic immunoglobulin M (cIgM) expression in all 9 children. Bone marrow smear examination demonstrated cytoplasmic vacuolization in 5 children. RNA sequencing detected 5 types of MEF2D gene fusion partners, including BCL9 gene in 4 children, FOXJ2 gene in 2 children, and 1 child each of DAZAP1 gene, SS18 gene, and ARNT gene. Heterozygous deletions of CDKN2A or CDKN2B gene were detected in 6 children, and 8 children exhibited concurrent gene variations. Induction therapy with the vincristine+daunorubicin+L-asparaginase+prednisone (VDLP) regimen was administered to all 9 children in accordance with"the Clinical Practice Guideline for Childhood Acute Lymphoblastic Leukemia (2018)". At the end of induction remission therapy, minimal residual disease (MRD) assessed by flow cytometry were all negative (<0.01%) in all cases. One child was lost to follow-up during the maintenance phase. Three children experienced relapse and succumbed. The remaining 5 children were followed up until October 10, 2025, with 2 in disease-free survival and 3 still receiving regular treatment. Conclusions: B-ALL with MEF2D gene rearrangement predominantly affects older children, typically presenting with fever accompanied by arthralgia. This subtype exhibits high CD38 expression and absence of cIgM expression, with a frequent incidence of CDKN2A or CDKN2B gene deletions. Although the initial treatment response was good, the risk of recurrence was high and the efficacy of salvage treatment was limited. For this high-risk sub-type, the use of next-generation sequencing for MRD monitoring could be explored to more accurately assess the risk of relapse. 目的: 总结伴有肌细胞增强因子2D(MEF2D)基因重排的儿童急性B淋巴细胞白血病(B-ALL)的临床特点、分子遗传学特征及诊治要点。 方法: 病例系列研究。收集2020年5月至2025年6月郑州大学第一附属医院收治的9例伴有MEF2D基因重排的初诊B-ALL患儿的资料,分析其临床特征、实验室检查、治疗及转归情况。 结果: 9例患儿男3例、女6例,诊断年龄12.0(11.0,13.8)岁,5例以发热伴关节疼痛起病。免疫分型提示1例为早期前B-ALL,其余8例为普通B-ALL;9例均高表达CD38,不表达胞质免疫球蛋白M(cIgM)。5例骨髓涂片可见细胞伴有空泡。RNA测序检测到5种MEF2D基因融合伙伴,分别为BCL9基因4例,FOXJ2基因2例,DAZAP1基因、SS18基因及ARNT基因各1例。6例检出CDKN2A或CDKN2B基因杂合缺失,8例合并基因变异。9例患儿均按照2018儿童急性淋巴细胞白血病诊疗规范给予VDLP(长春新碱、柔红霉素、培门冬酶、泼尼松)方案诱导治疗,诱导缓解治疗结束时经流式细胞术检测微小残留病均阴性(<0.01%)。1例患儿维持治疗阶段失访,3例复发后死亡,随访至2025年10月10日2例无病生存,3例规律治疗中。 结论: 伴有MEF2D基因重排的B-ALL多见于大龄儿童,常以发热伴关节疼痛起病,高表达CD38,不表达cIgM,CDKN2A或CDKN2B基因缺失发生率高。尽管初始治疗反应良好,但复发风险高且挽救治疗疗效有限,采用二代测序进行微小残留病监测或许可更准确评估复发风险。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jia XP, Lian AN, Zhang YS, et al. [Clinical analysis of 9 children of B-cell acute lymphoblastic leukemia with MEF2D gene rearrangement]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42527140. doi:10.3760/cma.j.cn112140-20251230-01163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。